PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25859173-0	2015	Continuous Inhalation of Ipratropium Bromide for Acute Asthma Refractory to beta2-agonist Treatment.	Ipratropium	25-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	76-81	
6219156-9	1983	It is concluded that when the anticholinergic drug ipratropium is administered concurrently with an inhaled beta 2 agonist and an oral theophylline derivative, increased bronchodilatation occurs with no detectable additional side effects.	Ipratropium	51-62	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	108-114	
28824036-1	2017	BACKGROUND: Inhaled anticholinergics such as ipratropium bromide (IB), when administered with beta2-agonists, are effective in reducing hospital admissions of children presenting to the emergency department with moderate to severe asthma.	Ipratropium	45-64	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-99	
28824036-1	2017	BACKGROUND: Inhaled anticholinergics such as ipratropium bromide (IB), when administered with beta2-agonists, are effective in reducing hospital admissions of children presenting to the emergency department with moderate to severe asthma.	Ipratropium	66-68	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-99	
25859173-1	2015	To present the case of a patient with persistent bronchospasm, refractory to treatment with beta2-agonists, that resolved promptly with continuous inhalation of large dose (1000 mcg/hr) ipratropium bromide, and to discuss the possibility of tolerance to beta2-agonists as the cause for his failure to respond to adrenergic medications.	Ipratropium	186-205	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	92-97	
25859173-1	2015	To present the case of a patient with persistent bronchospasm, refractory to treatment with beta2-agonists, that resolved promptly with continuous inhalation of large dose (1000 mcg/hr) ipratropium bromide, and to discuss the possibility of tolerance to beta2-agonists as the cause for his failure to respond to adrenergic medications.	Ipratropium	186-205	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	254-259	
25859173-6	2015	Continuous inhalation of large dose ipratropium bromide may be an effective regimen for the treatment of patients hospitalized with acute asthma who are deemed to be nonresponsive and/or tolerant to beta2-agonist therapy.	Ipratropium	36-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	199-204	
16129327-4	2005	Ipratropium bromide can be added in the nebulisation, depending on the severity of the attack and the response to beta-2-agonists.	Ipratropium	0-19	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	114-120	
23656745-8	2013	Nebulised ipratropium bromide (via nebulisation or multidosing via pMDI-spacer combination) should be added if there is a poor response to three doses of beta2-agonist or if the symptoms are severe.	Ipratropium	10-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	154-159	
16625543-15	2006	Combination therapy with ipratropium plus a short-acting beta-2 agonist conferred benefits over a short-acting beta-2 agonist alone in terms of post-bronchodilator lung function.	Ipratropium	25-36	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	111-117	
16625543-17	2006	AUTHORS" CONCLUSIONS: The available data from the trials included in this review suggest that the advantage of regular long term use of ipratropium alone or in combination with a short-acting beta-2 agonist or over a beta-2 agonist alone are small, if the aim is to improve lung function, symptoms and exercise tolerance.	Ipratropium	136-147	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	217-223	
21728272-1	2011	BACKGROUND: The addition of ipratropium, a synthetic cholinergic antagonist, to beta2-agonist therapy provides an additive improvement in adult with acute severe asthma and COPD because of increased vagal tone in the airways.	Ipratropium	28-39	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	80-85	
11714074-7	2001	Use of nebulized ipratropium/beta2-agonist combination therapy was associated with a pooled 7.3% improvement in forced expiratory volume in 1 sec [95% confidence interval (CI), 3.8-10.9%] and a 22.1% improvement in peak expiratory flow (95% CI, 11.0-33.2%) compared with patients who received beta2-agonist without ipratropium.	Ipratropium	17-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	293-298	
11980113-10	2002	CONCLUSION: Severe complication of BA is treated more effectively with combination of beta 2-adrenomimetic with atrovent.	Ipratropium	112-120	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	86-92	
15500180-4	2004	Anticholinergic bronchodilators, such as ipratropium bromide and especially tiotropium, are first-line anticholinergic agents that can be used alone or in combination with long-acting or short-acting beta2-agonists to achieve these primary goals of COPD treatment.	Ipratropium	41-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	200-205	
12395958-1	2002	OBJECTIVE: To determine whether a combined formulation consisting of ipratropium and an inhaled beta2 agonist (2-in-1 therapy) leads to lower respiratory-related healthcare use and charges and improved compliance compared with treatment with separate ipratropium and beta2-agonist inhalers (separate inhaler therapy).	Ipratropium	69-80	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	267-272	
11714074-7	2001	Use of nebulized ipratropium/beta2-agonist combination therapy was associated with a pooled 7.3% improvement in forced expiratory volume in 1 sec [95% confidence interval (CI), 3.8-10.9%] and a 22.1% improvement in peak expiratory flow (95% CI, 11.0-33.2%) compared with patients who received beta2-agonist without ipratropium.	Ipratropium	315-326	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-34	
1835292-8	1991	Ipratropium may also be effective when beta 2 agonists are not effective.	Ipratropium	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	39-45	
11718499-5	2001	Ipratropium should be considered in patients who fail or cannot tolerate beta2-agonists.	Ipratropium	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-78	
11303413-9	2001	Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol).	Ipratropium	216-227	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	189-195	
9400690-8	1997	Thus, nebulized ipratropium bromide imparts a small improvement in lung function when compared with salbutamol alone; however, further studies are needed to determine if multiple doses of combined anticholinergic/beta 2-agonist treatment reduce need for admission.	Ipratropium	16-35	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	213-219	
8966503-4	1996	In an overview the action, indications and side effects of beta-2 sympathomimetics, ipratropium bromide, anti-allergens and inhaled steroids are discussed.	Ipratropium	84-103	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-65	
1840360-7	1991	One of the advantages of adding ipratropium to nebulised beta-agonist treatment might be that it permits the use of lower doses of beta 2-agonist and thereby reduces the systemic side-effects of the treatment.	Ipratropium	32-43	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	131-137	
2962075-5	1987	Studies indicate that ipratropium bromide is effective in some pre-term babies who have airways obstruction following positive pressure ventilation but it can be a useful agent in the first 18 months of life, when beta 2-stimulants are rarely effective.	Ipratropium	22-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	214-220	
2882568-2	1986	The studies suggest that the use of a combination of anticholinergic and beta 2-adrenergic drugs is justified, because the dominant mechanism in bronchospasm is the effect of acetylcholine on muscarinic receptors and because ipratropium bromide increases the action of fenoterol, so as to obtain prolonged bronchospasmolytic and antibronchoconstrictive effects with halved doses of beta 2-agonist.	Ipratropium	225-244	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79